Moderna: departure of sales director in sight
The messenger RNA specialist intends to concentrate on the continued sales of its Covid-19 vaccine, Spikevax, and the launch of its RSV vaccine in 2024, while preparing to launch several products a year from 2025.
To this end, CEO Stéphane Bancel will take over responsibility for sales and marketing in 2024, in direct liaison with the commercial team, and Stephen Hoge will assume responsibility for pipeline commercial strategy and medical affairs.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction